Podcasts about sems

ASV prezidents Donalds Tramps ir tik aktīvi strādājis un runājis, ka šoreiz raidījums Divas puslodes ir par Amerikas Savienotajām Valstīm. Protams, ne tikai par tām, jo Tramps mēģina ietekmēt visu pasauli. Pirmkārt, viņš to dara, izmantojot kā ieroci muitas tarifus. Sācis ar Kanādu, ar Meksiku un ar Ķīnu. Tiesa, pirmajām divām valstīm lēmuma īstenošana ir par mēnesi atlikta. Nākamais viņa šantāžas upuris varētu būt Eiropas Savienība. Eiropas virzienā raugoties, Tramps grib mainīt ne tikai tirdzniecības bilanci, bet arī atņemt Dānijai lielāko salu pasaulē Grenlandi. Viņš esot apņēmies panākt, ka Grenlande būs ASV īpašumā. Tāpat Trampu interesē atgūt kontroli pār Panamas kanālu.  Norises pasaulē analizē Jānis Kapustāns, Latvijas Nacionālās aizsardzības akadēmijas pasniedzējs, un Sigita Struberga, Latvijas Transatlantiskās organizācijas ģenerālsekretāre. Grenlandi gribu! Vikingu kuģotāji, kuri 10. gadsimta nogalē piestāja pie Grenlandes krastiem, lika pamatus šīs pasaulē lielākās salas tūkstoš gadus ilgajām saiknēm ar Skandināviju. 1775. gadā toreizējā Dānijas-Norvēģijas apvienotā karaliste pasludināja Grenlandi par savu koloniālo valdījumu, un pēc tam, kad Norvēģija 1814. gadā apvienojās ar Zviedriju, sala palika Dānijas kroņa zeme. Liela daļa tās teritorijas gan ilgi bija neizpētīta un nekartēta, tāpēc pilnvērtīgu suverenitāti pār Grenlandi Dānija nodibināja tikai pagājušā gadsimta divdesmitajos gados. Sākot ar septiņdesmitajiem gadiem iesākās Grenlandes autonomizācijas process, kura pēdējais etaps noslēdzās ar 2009. gada Pašpārvaldes aktu. Grenlande ieguva plašu autonomiju, atstājot kādreizējās metropoles ziņā tikai ārējās drošības, monetārās politikas un daļu no ārlietu jautājumiem. Kopš tā laika spēkā pieņēmusies kustība par pilnīgu Grenlandes neatkarību, aptaujas liecina, ka par to ir vairāk nekā puse no salas iedzīvotājiem, un līdz nesenam laikam šo ideju atbalstīja arī pašreizējā autonomijas valdība ar premjeru Mūti Bouropu Egedi priekšgalā. Vēl šī gada sākumā tika plānots, ka neatkarības referendums varētu notikt vienlaicīgi ar Grenlandes parlamenta vēlēšanām aprīļa sākumā, taču ideja šķiet nolikta malā kopš brīža, kad savu agresīvo Grenlandes iegūšanas kampaņu uzsāka Donalds Tramps. Viņš šai ziņā nav nekāds pirmatklājējs – ideja atpirkt salu no Dānijas aktualizēta vairakkārt. Atbilde no Kopenhāgenas, kā arī šajā reizē, allaž ir bijusi, ka Grenlande netiek pārdota. Tomēr nekad agrāk no Vašingtonas nav izskanējusi tik agresīva retorika, kāda tā ir patlaban, konkrēti draudot Dānijai ar milzīgiem ievedmuitas tarifiem un neizslēdzot pat militāra spēka lietošanu. Var atgādināt, ka Savienoto Valstu militārā klātbūtne Grenlandē pastāv jau šobrīd un balstās 1951. gada nolīgumā, saskaņā ar kuru Dānija piekrīt ASV bāzu izvietošanai, pretī saņemot garantijas aizsargāt salu pret jebkādu ārēju iebrukumu. Atbildot uz prezidenta Trampa izteikumiem, Kopenhāgena paudusi gatavību visa veida sadarbībai drošības jomā un paziņojusi par nozīmīgu finansējuma palielināšanu Arktiskā reģiona aizsardzībai. Savukārt Grenlandes parlaments steidzamības kārtā pieņēmis likumu par ārvalstu vai nenosakāmas izcelsmes finansējuma aizliegumu politiskajām organizācijām. Tēvocis Sems kā deva, tā ņems (kanālu)! Savā pirmajā ārvalstu tūrē jaunais Savienoto Valstu valsts sekretārs Marko Rubio devās uz vairākām Centrālamerikas valstīm. Tūres degpunktā, protams, bija vizīte Panamā, kurai jaunievēlētais prezidents Tramps izvirzījis teju viennozīmīgas teritoriālas pretenzijas. Runa ir par kādreizējo Panamas kanāla zonu, kuru līdz 1999. gadam kontrolēja Savienotās Valstis. Amerika uzņēmās Atlantijas un Kluso okeānu savienojošā kanāla būvi pagājušā gadsimta sākumā, kad vairākas desmitgades iepriekš šo projektu pusceļā bija pametusi Francija. Tā kā finansējums, tehnoloģijas, organizācija un daļa darbaspēka nāca no Savienotajām Valstīm, šķita diezgan loģiski, ka pēc kanāla izbūves tam pieguļošās teritorijas nonāca Vašingtonas beztermiņa nomā. Var piebilst, ka pati Panamas valsts tapšana 1903. gadā ir saistīta ar kanāla projektu. Līdz tam Panama bija Kolumbijas Republikas sastāvdaļa, kas kļuva neatkarīga pēc tam, kad Savienotās Valstis ar militāras iejaukšanās draudiem piespieda Kolumbiju atzīt Panamas neatkarību. Taču 20. gs. otrajā pusē mazā Centrālamerikas valsts un tās sabiedrība vairs nebija gatava samierināties ar amerikāņu „servitūtu”, kas sašķēla Panamas teritoriju divās daļās. Pēc vairākiem asiņainiem protestiem kanāla zonā Amerika piekrita sarunām, un 1979. gadā tika parakstīta vienošanās par teritorijas pakāpenisku nodošanu pilnīgā Panamas suverenitātē. Tagad prezidents Tramps nepaguris klāsta, ka tā esot bijusi kļūda, ka Panama pārkāpjot vienošanos un vispār esot atdevusi kanālu ķīniešiem. Savienotās Valstis kā iedevušas, tā paņemšot kanālu atpakaļ. Tādējādi nenākas šaubīties par Marka Rubio un Panamas prezidenta Hozē Raula Mulino sarunu saturu. Panamas valsts galva apsolīja apzināt iespējamo Ķīnas interešu klātbūtni kanāla uzņēmumos un iespējas pārtraukt priekšlaicīgi līgumus ar Honkongā reģistrēto kompāniju, kas pārvalda ostas abos ūdensceļa galos, lai gan šo ostu darbība nav tieši saistīta ar paša kanāla funkcionēšanu. Tomēr viņš vēlreiz uzsvēris, ka Panamas kanāls ir un paliks viņa valsts suverena teritorija. Mēs sitīsim ar tarifiem, arvien, arvien! 1.februārī prezidenta Trampa piesolītā partneru slānīšana ar tarifu milnu šķita pieņemam konkrētākas aprises – Baltā nama saimnieks paziņoja, ka otrdien stāšoties spēkā 25% ievedmuitas tarifi Meksikas un Kanādas precēm, kā arī 10% importam no Ķīnas. Ekonomisti steidzās atgādināt par iespējamām nopietnām problēmām, ko šāds solis radīs pašu Savienoto Valstu ekonomikai. Taču jau pirmdien, 3. februārī, grandiozie plāni izrādījās atlikti vismaz uz mēnesi. Vispirms tika paziņots, ka Meksikas prezidente Klaudija Šēnbauma piekritusi nosūtīt 10 000 karavīru uz valsts ziemeļu robežu nelegālās migrācijas un narkotiku kontrabandas apkarošanai. Dienas otrajā pusē tādu pašu atlikšanu saņēma arī Kanāda pēc tam, kad premjerministrs Trudo bija aprunājies ar Trampu pa telefonu. Arī šajā gadījumā izšķirošais esot robežkontroles arguments, lai gan fentanila daudzums, kas Savienotajās Valstīs nonāk caur ziemeļu robežu, ir salīdzinoši niecīgs. Var piebilst, ka gan Kanāda, gan Meksika jau bija paziņojušas, ka amerikāņu tarifu ieviešanas gadījumā tās spers adekvātus atbildes soļus. Finanšu tirgi, kas pirmdienas rītu sagaidīja ar manāmu kritumu, pēc paziņojumiem par tarifu atlikšanu atgriezās normālā kondīcijā. Tikām Ķīna paziņojusi, ka tā savu 10% tarifu apstrīdēšot Pasaules Tirdzniecības organizācijā un noteikusi atsevišķiem Savienoto Valstu produktiem ievedmuitas tarifus līdz 15% apjomā. Tiek atzīmēts, ka starp šiem produktiem nav nozīmīgāko no ASV importējamo preču kategoriju. Dienaskārtībā ir arī jautājums par iespējamajiem tarifiem Eiropas Savienībai. Motīvu šai ziņā netrūkst, sākot ar Savienoto Valstu bilances deficītu tirdzniecībā ar apvienoto Eiropu, beidzot ar vēlmi tikt pie Grenlandes. Sagatavoja Eduards Liniņš.  

El 26 de septiembre se conmemora en nuestro país el Día Nacional para la Prevención del Embarazo no Planificado en Adolescentes. Este día tiene el propósito de sensibilizar a la población en general respecto al impacto del embarazo adolescente que trunca o afecta proyectos de vida, amplía las brechas sociales y de género, tiene importantes repercusiones en la salud y el desarrollo psicosocial; además, frena la incursión de niñas y jóvenes en la educación, y efectos negativos social y económicamente. En este podcast de El Expresso de las 10 trasladamos nuestros micrófonos a la preparatoria Regional de El Salto Jalisco desde donde conversamos con la Dra. Kimberly Viridiana Romero Delgado, Médica encargada de la estrategia EDUSEX del OPD/Servicios de salud Jalisco y la comunidad estudiantil de El Salto Jalisco en torno a Prevención de embarazos no planificados e ITS. Gracias a la Lic. Zaira Anaid Pantoja Díaz, Directora de la Preparatoria Regional de El Salto y a Xóchitl Margarita García Aguilar, Coordinadora Académica; gracias a SEMS, y a Mesa SEIS (Mesa de salud y educación integral de la sexualidad)

Rick Sems, newly named CEO of Wichita's Equity Bank, joined the podcast to talk about his career and the bank's direction after so many recent acquisitions.

Sems Sera Leisinger macht mit ihren Romanen auf benachteiligte Gruppen und Missstände aufmerksam. Im neuen Roman „Weißes Gold“ geht es um Albinos in Tansania, für die es dort lebensgefährlich ist. Sems Sera ist die offizielle Patin der Friedensnobelpreisträgerin Malala Yousafzai und hält regelmäßig Lesungen aus deren Buch „Ich bin Malala“. Ihr hört außerdem, was sie besonderes aus ihren eigenen Haaren gestrickt hat.

In this minisode, Remi joins Joe on the pod to talk about his position on the board and what films he recommends the most! (Sad Dad edition)--------The whole RSS feed is available here > https://rss.com/podcasts/thereelthingThe Reel Thing on Social Media:Instagram > https://www.instagram.com/thereelthingpod---------All music by Wise John. https://wisejohn.com/Follow them on Instagram > https://www.instagram.com/wisejohnofficial/---------Bergen Filmklubb > https://bergenfilmklubb.no/---------

In this episode, Christian Geiser and I embark on a journey to uncover the complexities and applications of SEMs, a statistical method that often flies under the radar at typical biostatistics conferences yet holds significant potential in research, particularly within psychology and social sciences. How do SEMs differ from traditional statistical methods? What makes them so valuable in dealing with measurement error and complex variable relationships? Join us as we explore these questions and more, shedding light on a tool that is both powerful and underutilized. We also discuss the following key points:

*91 ŞEMS SÛRESİ N026 M091 Mekke'de nâzil olmuştur. 15 âyettir. Güneşi, Ayı, gökyüzünü, yeryüzünü yaratan, Allah'ın mülkünde, Allah'ın kurallarına göre yaşanacak. Haksız yere kan akıtılmayacak. "Deveyi kesmeyin" dediği halde sırf peygambere muhalefet olsun diye deveyi kesen Semud kavminin helâk edilişi bildirilirken, bizler uyarılıyoruz. Rahmân ve Rahîm olan Allah'ın adı ile 1 And olsun Güneşe ve aydınlığına, 2 Ona (Güneşe) uyduğu zaman Ay'a, 3 Onu (Güneşi) açtığında gündüze, 4 Onu (Güneşi) sardığında geceye, 5 Gökyüzüne ve onu yapana, 6 Yeryüzüne ve onu döşeyene, 7 Nefse ve onu düzenleyene, 8 Ona facirliğini (suç işlemeyi) ve takvasını (korunmayı) ilham edene (yemin olsun ki)!, 9 Nefsini temizleyen, mutlaka kurtuldu. 10 Nefsini batıran zarar etti. 11 Semud (kavmi) azgınlığı sebebiyle (Salih'i) yalanladı. 12 (Semud kavminin) en şakisi (yerinden) fırladığında, 13 Onlara Allah'ın Rasûlü: "Allah'ın devesini ve onun sulanmasını gözetin" demişti. 14 Onu (Salih'i) yalanladılar ve deveyi kestiler. Bunun üzerine Rab'leri günahları sebebiyle onların üzerine azap gönderdi ve hepsini dümdüz etti. 15 Onun (Semud kavminin) sonucundan O (Allah) korkmaz. https://soundcloud.com/kuranikerimtefsiri/sems-suresi-tefsiri-ali-kucuk

Meeds, Jay, Timson and Sems discuss a blockbuster night at stamford bridge A 4-4 draw against Manchester City in a manic game was reviewed in depth as well as special mentions to top performers of the day. The lads also preview our trip to Newcastle and thoughts about where Nkunku and Lavia slot in. What we expect from Jackson this season in terms of goals and finally the Osimhen links. Tap in! Learn more about your ad choices. Visit megaphone.fm/adchoices

Meeds, Jay, Buzzi and Sems get their teeths into a delicious victory against the high flying Spuds in their backgardern. A 4-1 victory in a manic game was reviewed in depth as well as special mentions to top performers of the day. The lads also preview the big game against Man City at the Bridge on Sunday and thoughts about where Nkunku fits into all of this goodness. Tap in! Learn more about your ad choices. Visit megaphone.fm/adchoices

The Synth & Electronic Music Show episode 102 see the live meet-up team of Peter, Clive, Rhys & Seb discuss September's session at the pub! Features live music from: Untrained Dogman (Tom & Hannah) The Head Gardeners (Tim Cronin) Sebtic Smile & Osvos aka The Opposable Thumbs Shape Navigator AnalogueMechanic Mowgli Elliott Sirota-Gott Sophie Sirota

Our latest podcast recorded in Whitstable Harbour where Peter & Clive discuss September's SEMS live session with recordings from the evening.

Voice of the 'Cats Wyatt Thompson joins us on Fridays with football previews all season long.  Tommy and Jacob take a look at what to expect in tomorrow's game and broadcast on KFH.

G'day guys and welcome to once again another exciting episode!!! This week we sat down with our boy Sem Kakembo and delved into all things self development, the importance of community, brotherhood & social connections. We also reflect on Sems love for nature and how he takes practical steps to use nature as a form of meditation. We'd love to hear your opinions so please comment down below. If you enjoyed this episode or found it beneficial, don't forget to LIKE the video and SHARE it with others!! Follow us on our socials at: Instagram: https://www.instagram.com/fairdinkumau/ FaceBook: https://www.facebook.com/fairdinkumau Tik Tok: @fairdinkumau For the audio listeners out there: Apple Podcast: https://podcasts.apple.com/au/podcast... Spotify: https://open.spotify.com/show/2yRDjMv... PEACE!!!  

Sems and Meeds have a discussion after Chelsea's final Pre-season game against Dortmund, have a discussion about who has impressed this pre-season, new incomings and potential outgoings, and ultimately, who makes the final squad for the season. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Peter and Clive meet at the beach hut again to chat about our May meet-up session (SEMS) that featured Sebtic Smile & OSVoS, AnalogueMechanic, Shape Navigator, Sophoe Sirota and Elliot Sirota-Gott. It was also Clive's birthday so we had cake too!

The Synth & Electronic Music Show hasn't been made for ages so Peter & Clive headed down the beach hut for a catch up. The topic was about the fantastic International Drone Day event held on 27 May 2023 at The Gulbenkian Arts Centre in Canterbury where the SEMS meet-up went epic with drones with a big stage, big PA and even bigger visuals from@diz_qo who is in the process of editing some brilliant films from the night. More news on those to come and maybe more of the beach video chats if you like this one!

Google LSA expands to new categories & faces spam:  Google has added new, high value categories to their Local SErvice Ads program. They continue to target ever more service type businesses. While the pricing for this simpler product has gone up due to the added auction capabilities, in many markets it is still a good value. It is also important for service type businesses to watch for first mover opportunities in their local markets. With this link: Local Service Finder - Pro List businesses can assess which categories in which geographies have more opportunities. However in some urban, highly competitive markets like personal injury law & locksmiths, not only has pricing gone crazy, spam has as well. Google has added a new LSA spam review reporting form to cope with some of the fake review issues. ChatGPT making rapid and differentiating inroads into SAAS tools for Local:  The players in the local space have all become pretty similar to each other offering listings, review management, Google Posts with little to distinguish them. But with the advent of large language models in general and ChatGPT specifically, many have begun to offer unique tools on top of their core products that leverage the generative AI capabilities. The value of generative AI will first be realized in the SAAS world where the benefits can be easily added to existing products to increase business productivity. Hubspot's ChatUX shows how this can be integrated into a CMS and Uberall shows how it can improve access to a company's granular data like inventory. Why every company needs a “how we use AI” FAQ:  Wired recently published an article on how they will use generative AI tools vis a vis their written and visual content. They detail whether they will use AI to write or edit articles (they won't), whether they will use it to generate ideas and headlines (they might) and whether they will use it to create story graphics (they won't due to artists not receiving royalties).Jennifer Slegg on Twitter, using a  creative Google search, demonstrated just how many businesses are currently using generative AI and blindly copying and pasting it onto their websites. This raises the question of whether not just Wired but everyone that creates content - writers, SEO firms, SEMs and more - should consider both an internal code of ethics and a forward facing statement of those values.The Near Memo is a weekly conversation about Search, Social, and Commerce: What happened, why it matters, and the implications for local businesses and national brands.near memo ep 104Subscribe to our 3x per week newsletter at https://www.nearmedia.co/subscribe/

La adolescencia entre los 10 y 19 años, se caracteriza por una fase de cambios, donde abundan las preguntas y donde nacen las curiosidades. Muchos de esos cambios son relacionados con la sexualidad y la evolución física que su cuerpo empieza a experimentar.El proyecto “One to sex… sexualidad paso a paso” busca proveer de información completa y confiable los entornos donde se desenvuelven los estudiantes de Prepas UDG… Y hoy El Expresso de las 10 se suma a esta iniciativa para lo que trasladamos nuestros micrófonos a la Preparatoria número 8, esto es “One to sex… en El Expresso de las 10”.

La adolescencia entre los 10 y 19 años, se caracteriza por una fase de cambios, donde abundan las preguntas y donde nacen las curiosidades. Muchos de esos cambios son relacionados con la sexualidad y la evolución física que su cuerpo empieza a experimentar. El proyecto “One to sex… sexualidad paso a paso” busca proveer de […] La entrada ONE THE SEX… SEXUALIDAD PASO A PASO – SEMS – El Expresso de las 10 – Ju. 16 Feb 2023 se publicó primero en UDG TV.

Nûçegihana me Hatîce Kamer di raporta xwe ya îro de ji me re behsa serpêhatiya erdhejînê û bandora wê li ser derûniya wê dike. Her weha derbarê erdhejîna li Amedê, Semsûrê û deverên din jî nûçeyên herî dawî radigihîne.

Música

Ir ne tikai dzejas, bet arī kino rudens Latvijā. Ar Aika Karapetjana filmas "Sema ceļojumi" pirmizrādi sākas latviešu kino rudens maratons. Latvijas kino rudeni raksturo režisori, kuru filmas drīzumā redzēsim kinoteātros. Aika Karapetjana filma "Sema ceļojumi" ir asa alegorija. Stāsts ir par vīrieti vārdā Semjuels, īsāk, Sems, viņš tiek ļoti diskrēti pasniegts kā vienkāršs eiropietis. Arī filmas darbībā  netiek akcentēts, ka šis stāsts notiek Latvijā, tātad tā ir bezmaz tāda Kārļa Skalbes stila zeme, kurā cilvēki ir ļoti vienkārši, ļoti drastiski. Viņi audzē cūkas, un viņu uzskati par to, kāda ir lietu kārtība, ir ļoti īpatnēja. Aika Karapetjana filmas "Sema ceļojumi" pirmizrāde jau 8. septembrī. Filma "Mamma vēl smaida". Režisore Elza Gauja, trīs aktrises - Baiba Broka, Anta Aizupe un Daiga Kažociņa, kuras ir arī scenārija līdzautores. Stāsts ir par trim māsām, kurām viņa mamma aiziet mūžībā kādā Eiropas valstī, nav precizēts kurā. Meitas nolemj, protams, mamma jāgulda Latvijas zemē. Taču dažādām oficiālām procedūrām naudas nepietiek, un tā sākas ceļojums cauri Eiropai ar mašīnu un mammu.. jumta bagāžniekā. Tāds ir Elzas Gaujas stāsts. Filmas "Mamma vēl smaida" pirmizrāde 29. septembrī.  Staņislava Tokolova filma "Mīlulis". Šis ir vairāk sociāli aktuāls stāsts par jaunu un ambiciozu maksātnespējas administratoru. Šis jaunais vīrietis piedzīvo emocionālu triecienu, proti, iet bojā viņa draudzene, un jaunajam vīrietim ir jāuzņemas atbildība gan par viņas dārgo īpašumu, gan arī par 10 gadus veco meitu Paulu. Galvenajā lomā Kārlis Arnolds Avots. Vēl redzēsim arī Kristīni Krūzi un Paulu Lābani, kurai tā ir debija uz lielā ekrāna. Attiecību drāmas "Mīlulis" pirmizrāde 21. septembrī. Savukārt no 16. septembra kinoteātros visā Latvijā būs skatāms vēsturisks spiegu trilleris "Suflieris" ar Prītu Voigemastu, Agnesi Budovsku un Kasparu Znotiņu galvenajās lomās.  Filma ir Latvijas, Igaunijas, Somijas un Lietuvas kopražojums, kurā atspoguļota Otrā pasaules kara priekšvakara spriedze. Bet no 4. oktobrī pirmizrāde Uģa Oltes filmai "Upurga". Šis stāsts un kuru devīze ir mitoloģisks trilleris dabā, ir par piedzīvojumu gidu Andreju, kurš mežonīgas upes ielejā pazaudē savu māsu un viņas kolēģus - reklāmu filmēšanas grupu. Un neviens no filmas varoņiem nezina, ka šajā ielejā rudeņos parādās, uzplaukst kāda dabas parādība, kurai piemīt neprātīgs spēks.  Vēl par darbu pie diviem jauniem kinostāstiem stāsta operatos Aleksandrs Grebņevs: tās ir Matīsa Kažas jauniešu drāma "Neona pavasaris" un režisores Lindas Oltes pusaudžu adopcijas stāsts "Māsas". Kopumā līdz gada beigām gaidāmas pirmizrādes 20 jauniem darbiem, spēlfilmām un dokumentālā kino stāstiem.

Šī gada 8. septembrī kinoteātrī “Forum Cinemas” pirmizrādi piedzīvos studijas “Mistrus Media” un režisora Aika Karapetjana jaunākā spēlfilma “Sema ceļojumi”, kas stāsta par ārzemnieku Semu, kurš dodas uz kādu nomaļu Eiropas vietu meklēt savu tēvu. Tomēr meklējumi ieved viņu pasaulē, kādu viņš nav iepriekš pieredzējis. Negaidītu situācijas pavērsienu rezultātā Sems nonāk kādas zemnieku ģimenes gūstā, no kurienes viņu, kā izrādās, var glābt tikai kāds mazs sivēns. Vārdu sakot - pasaka pieaugušajiem par cūkām un svešiniekiem! Šovakar uz sarunu raidījumā viesosies filmas producents Gints Grūbe un dzīvnieku trenere Daina Matskina. Jau ziņots, ka Latvijas un Beļģijas kopprodukcijas filma “Sema ceļojumi”, ko veidojusi Latvijas filmu studija “Mistrus Media” kopprodukcijā ar Beļģijas kompāniju “Polar Bear”, izpelnījusies arī ietekmīgā televīzijas tīkla “HBO Europe” ievērību – tas iegādājies filmas demonstrēšanas tiesības, tādējādi apliecinot latviešu filmas kinemotogrāfisko un saturisko vērtību. Filmā galveno lomu atveido Eiropas kino populārais beļģu aktieris Kevins Jansens, kurš filmējies tādos populāros kinodarbos kā režisores Koralijas Feržē filmā “Atriebība” un Kristiana Volkmana “Slepenā istaba”. Filmā “Sema ceļojumi” lomas atveido arī jauni un daudzsološi, kā arī pieredzējuši un jau iemīļoti latviešu aktieri – Laura Siliņa, Aigars Vilims, Juris Bartkevičs, Normunds Griestiņš. Operators ir Jurģis Kmins (“Bille”, “1906” u. c.), galvenais mākslinieks – Jurģis Krāsons, grima māksliniece – Maija Gundare, kostīmu māksliniece – Liene Dobrāja, producenti – Gints Grūbe un Inese Boka-Grūbe (“Melānijas hronika”, “Tēvs Nakts”, “Janvāris” u. c.). KŪL| Kultūras ūnijas laiks ir eksperimentāls aktuālās mākslas un dzīves kultūras telpā skaidrojošs, ilustrējošs un dokumentējošs Radio NABA raidījums. Raidījums tiek veidots ar mērķi aplūkot un fiksēt aktuālos kultūras un laikmetīgās mākslas notikumus. Tā ir iknedēļas tikšanās vieta kultūras dzīves veidotājiem, māksliniekiem, režisoriem, studentiem, pētniekiem, lai runātu, kā rodas dažādās kultūras izpausmes formas. Raidījums Radio NABA programmā ir dzirdams trešdienās plkst. 19:00, raidījumu vada un producē Anete Enikova. Raidījuma aktualitātēm var sekot līdzi facebook.com/nabakul un instagram.com/naba.kul. Raidījuma ieraksti pieejami arī Spotify, iTunes un LSM arhīvā. Raidījums tapis ar “Valsts Kultūrkapitāla fonda” atbalstu.

Pēc gadu ilgas pauzes ar plašu kultūras programmu Rojā atgriežas kino, mākslas un mūzikas festivāls "RojaL", kas norisināsies no 28. līdz 30. jūlijam. “Kā ierasts, festivālu mēs atklāsim ar mākslas darbu, un tas notiks vēl pirms oficiālās festivāla atklāšanas,” Kultūras rondo stāsta māksliniece Envija. Viņas veidoto trīsdimensionālo instalāciju "Morandi: Gods būt" būs iespējams apskatīt Rojas pludmalē. “Pati šo darbu es saucu par būri – tas ir veidots kā piemineklis māksliniekam Džordžo Morandi.” Morandi ir itāļu mākslinieks, un, kā stāsta "RojaL" izpilddirektore Dārta Krāsone, festivāla veidotāji ik gadu cenšas izvēlēties vienu valsti, kam tiek pievērsta īpaša uzmanība. Ja 2020. gadā tās bija Baltijas valstis, tad šoreiz izvēle kritusi par labu Itālijai.  No bagātīgās festivāla programmas Dace Krāsone īpaši izceļ vairākos starptautiskos kinofestivālos augsti novērtēto režisora Aika Karapetjana jauno filmu "Sema ceļojumi". Tā ir savdabīga pasaka pieaugušajiem - melnā komēdija. Pēc kinolentes veidotāju paustā, filma stāsta par beļģi Semu, kurš dodas uz kādu nomaļu Eiropas vietu meklēt savu tēvu. Tēva meklējumi ieved viņu pasaulē, kādu Sems nav iepriekš pieredzējis. Negaidītu situācijas pavērsienu rezultātā beļģis nonāk kādas zemnieku ģimenes gūstā, no kurienes viņu, kā izrādās, var glābt tikai kāds mazs sivēns. Kā norāda filmas veidotāji, filmas tapšanā izmantoti dažādi oriģināli kinemotogrāfijas paņēmieni, lai vienlaicīgi runātu par tādām klasiskām tēmām kā mīlestība, brīvība, naids, greizsirdība. Festivāls noslēgsies sestdien, 30. jūlijā, ar jauno režisoru īsfilmu konkursa balvu pasniegšanas ceremoniju, Rojas pludmalē tiks pasniegti diplomi un notiks saulrieta koncerts, kam vēlāk vēl sekos filmu "Wild East. Kur vedīs ceļš" un "Astoņarpus" seansi. Visu "RojaL" programmu var skatīt festivāla mājas lapā: https://rojal.lv/lv. Tāpat kā citus gadus, arī šoreiz interesenti visus festivāla pasākumus var apmeklēt bez maksas.

Featuring recordings from our second meet up session with performances from Adam Smith, Clive Walpole, Peter Coyte, Sebastian Smith and Rhys Norster

Ben Sems first homer with Fresno

The scanning electron microscope (SEM) uses a focused beam of high-energy electrons to generate a variety of signals at the surface of solid specimens. The signals that derive from electron-sample interactions reveal information about the sample including external morphology (texture), chemical composition, crystalline structure and orientation of materials making up the sample.   Check out our MSE Company Database and free professional development guide for materials scientists and engineers!   In today's episode, Dr. Neal Magdefrau, owner of Electron Microscopy Innovative Technologies LLC (Emit, LLC), shares his knowledge about how Emit specializes in renting portable scanning electron microscopes.   In this conversation, we discuss:  

As Brian returns from down under, and with the Detroit show just around the corner, the FDI cools and the fastener world reconsiders its supply chain.  Industry veteran Preston Boyd of the Industrial Fasteners Institute describes how his organization is reaching out to distributors to reintroduce domestic suppliers (1:39:47).  Scanwell Logistics senior expeditor Chris Donnell explains a wide range of pressures on imports that suggests no improvement for inbound shipments in the foreseeable future (15:41).  Industry newsman Mike McNulty welcomes Sems & Specials VP of sales Kelly Charles as guest commentator on the Fastener News Report (1:00:19).  Thread guru Carmen Vertullo makes a generous offer of mentorship on the Fastener Training Minute (1:28:21).  The boys scramble to hold it all together as they prepare to hit the road for the motor city.  Run time:  02:25:29

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Open Problems in Negative Side Effect Minimization, published by Fabian Schimpf on May 6, 2022 on The AI Alignment Forum. Acknowledgments We want to thank Stuart Armstrong, Remmelt Ellen, David Lindner, Michal Pokorny, Achyuta Rajaram, Adam Shimi, and Alex Turner for helpful discussions and valuable feedback on earlier drafts of this post. Fabian Schimpf and Lukas Fluri are part of this year's edition of the AI Safety Camp. Our gratitude goes to the camp organizers: Remmelt Ellen, Sai Joseph, Adam Shimi, and Kristi Uustalu. TLDR; Negative side effects are one class of threats that misaligned AGIs pose to humanity. Many different approaches have been proposed to mitigate or prevent AI systems from having negative side effects. In this post, we present three requirements that a side-effect minimization method (SEM) should fulfill to be applied in the real world and argue that current methods do not yet satisfy these requirements. We also propose future work that could help to solve these requirements. Introduction Avoiding negative side-effects of agents acting in environments has been a core problem in AI safety since the field started to be formalized. Therefore, as part of our AI safety camp project, we took a closer look at state-of-the-art approaches like AUP and Relative Reachability. After months of discussions, we realized that we were confused about how these (and similar methods) could be used to solve problems we care about outside the scope of the typical grid-world environments. We formalized these discussions into distinct desiderata that we believe are currently not sufficiently addressed and, in part, maybe even overlooked. This post attempts to summarize these points and provide structured arguments to support our critique. Of course, we expect to be partially wrong about this, as we updated our beliefs even while writing up this post. We welcome any feedback or additional input to this post. The sections after the summary table and anticipated questions contain our reasoning for the selected open problems and do not need to be read in order. Background The following paragraphs make heavy use of the following terms and side-effect minimization methods (SEMs). For a more detailed explanation we refer to the provided links MDP: A Markov Decision Process is a 5-tuple ⟨S,A,T,R,γ⟩ In the setting of side-effect minimization, the goal generally is to maximize the cumulative reward without causing (negative) side-effects. RR: In its simplest form Stepwise Relative Reachability is an SEM, acting in MDPs, which tries to avoid side-effects by replacing the old reward function R with the compositionr(st,at,st+1)=R(st,at,st+1)−λdRR(st+1,s′t+1) where dRR(st+1,s′t+1)=1|S|∑s∈Smax(R(s′st+1;s)−R(st+1;s),0) is a deviation measure punishing the agent if the average “reachability” of all states of the MDP has been decreased by taking action at compared to taking a baseline action anop (like doing nothing). The idea is that side-effects reduce the reachability of certain states (i.e. breaking a vase makes all states that require an intact vase unreachable) and punishing such a decrease in reachability hence also punishes the agent for side-effects. AUP: Attainable Utility Preservation (see also here and here) is an SEM, acting in MDPs, which tries to avoid side-effects by replacing the old reward function R with the composition r(st,at,st+1)=R(st,at,st+1)−λdAUP(st,at,st+1) where dAUP(st,at,st+1)=1N∑Ri=1|QRi(st,at,st+1−QRi(st,anop,s′t+1)| is a normalized deviation measure punishing the agent if its ability to maximize any of its provided auxiliary reward functions Ri∈R changes by taking action at compared to taking a baseline action anop (like doing nothing). The idea is that the true (side-effect free) reward function (which is very hard to specify) is correlated with many ...

#marketing #landingpage #leadgen Episode 52 of the Point of View podcast. I sit down with marketing performance and affiliate marketing expert, Ian Fernando to talk about this career, but more importantly I ask him what makes a lead generation page go from 0 to 100! Chapters 0:00 - Intro 2:05 - Who is Ian Fernando 3:05 - Where will Ian travel in Southeast Asia? 5:45 - Main lesson in building a 6-7 online figure business 8:20 - Why businesses seek out marketing professional experts 10:44 - The common mistakes marketers make in their lead gen page? 12:48 - Tools to use to help measure success on your lead generation page 14:26 - The anatomy of a landing page, the strategy 16:15 - How to create a lead gen page for SEMs 24:05 - 2022 ad spend media buy predictions 29:33 - Email marketing effectiveness in 2022 test test test 33:21 - Advice to a c-suite or even a smaller business to improve their lead gen in order to sell their product / service, what's the key things you would advise them to review or look at? Links to reach out to Ian Fernando: LinkedIn: https://www.linkedin.com/in/ifernando/ Website: https://www.ianfernando.com/ Instagram: https://www.instagram.com/ianternet/ Facebook: https://www.facebook.com/IANternetMedia/ YouTube: https://www.youtube.com/user/iantrepreneur

In the words of Thin Lizzy, the boys are back. We're super happy to have our diocesan seminarians home for the Christmas break.  Welcome Sam Martinez to the show! Come to the Cupertino Classic, Priests vs. Sems basketball game!

In this episode, our CEO Neil Carberry interviews Anne Kiem, Chief Executive of the Chartered Association of Business Schools and Executive Director of the Small Business Charter. They discuss how we can improve business management, how to seek productivity as we bounce back from Covid-19 and adapt to Brexit, and how to solve long-term productivity challenges that we have faced in the UK. In this episode, tune in to hear: *How we can improve the performance of the UK economy for businesses of all sizes *More about the Government-backed 12-week programme - Help to grow: Management for SME leaders, which is helping SEMs achieve growth by providing Business Mentors * Why sustainability is important to the future of your business and its growth

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world's leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's podcast, 4 Cancer.Net Specialty Editors discuss new research in prostate, bladder, kidney, and testicular cancers presented at the 2021 Genitourinary Cancers Symposium, and 2021 ASCO Annual Meeting. This episode has been adapted from the recording of a live Cancer.Net webinar, held June 16th, 2021, and led by Dr. Neeraj Agarwal, Dr. Tian Zhang, Dr. Petros Grivas, and Dr. Timothy Gilligan. Dr. Agarwal directs the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine. He is also an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center. Dr. Zhang is an associate professor of medicine at Duke University School of Medicine and is a medical oncologist at Duke Cancer Institute. Dr. Gilligan is an Associate Professor and Medical Oncologist at the Cleveland Clinic Taussig Cancer Institute. Full disclosures for Dr. Agarwal, Dr. Grivas, Dr. Zhang, and Dr. Gilligan are available at Cancer.Net. Greg Guthrie: So today, let's introduce our participants. First we have Dr. Neeraj Agarwal of Huntsman Cancer Institute and University of Utah and the Cancer.Net Specialty Editor for Prostate Cancer. Next we have Dr. Petros Grivas from Fred Hutchinson Cancer Research Center and University of Washington. He is the Specialty Editor for Cancer.Net for Bladder Cancer. Next we have Dr. Tian Zhang of Duke Cancer Institute. And she's our Cancer.Net Specialty Editor for Kidney Cancer. And last, we have Dr. Timothy Gilligan. He is with the Cleveland Clinical Taussig Cancer Institute and the Specialty Editor for Testicular Cancer. So to start off, we'll have Dr. Agarwal talking about prostate cancer. Dr. Agarwal: Thank you, Greg. It's such a privilege and honor to be here discussing these studies. So I would like to start with the first study, which was led by Dr. Stephen Freedland, a urologist at the Cedars-Sinai Medical Center in Los Angeles and was co-authored by me, Dr. Dan George, and many others. And here in this study, we present the utilization of therapies, which are associated and known to be associated with very significant, in fact, I would say dramatic improvement in overall survival, as shown by multiple randomized control trials over the period of the last 5 to 6 years. Just to take a step back for the audience, until 2014, standard treatment for metastatic castration-sensitive prostate cancer or newly diagnosed metastatic castration-sensitive prostate cancer used to be androgen deprivation therapy. And combining androgen deprivation therapy with those medications which were approved in the castration-resistant metastatic prostate cancer setting. So basically, using those drugs upfront led to dramatic improvement in overall survival with 33% to 35% reduction in risk of death across those clinical trials. So we actually wanted to look at the real-world utilization, so look at the real-world users of these medications in these patients who are being diagnosed with -- newly diagnosed metastatic prostate cancer in the United States. We also wanted to see how patients who belong to minority populations or racial minority populations, how they are being treated with these medications, which are backed by level 1 evidence. So this was a retrospective analysis of a Medicare database, more than 35,000 patients were included from 2009 to 2018. And we can see here a very representative patient population, predominantly white patients, 11.8% were African American, and 5% were Hispanic. And here are the results. From 2010 to 2014, the use of standard androgen deprivation therapy with bicalutamide, was used in 97% of patients. We did not have trials reporting by that. Let's go to 2015 to 2016. Docetaxel was already approved in this setting now, and we can see some patients received docetaxel, but a small minority of patients received docetaxel. And then let's move to 2018, which is 4 or 5 years after docetaxel data had been presented by Dr. Sweeney in the ASCO plenary session. And abirateron was approved in 2017, and we are still seeing even like almost 2 years after -- we are still seeing the vast majority of patients being treated with standard androgen deprivation therapy or standard deprivation therapy with bicalutamide. So 62% plus 19%, we are talking about almost 80% of patients still not being treated with standard of care treatment, which is androgen deprivation therapy plus docetaxel, or androgen deprivation therapy plus abiraterone at this point of time, and now we have 2 more drugs available, which include enzalutamide and apalutamide in this study. Another interesting thing was if you look at the patients who belong to minority populations, so let's look at African American patients compared to Caucasian patients. The use of intensified therapy was numerically lower. So in Caucasian patients, we are seeing higher use of intensified, as we call them, intensified therapy, or therapies which are considered standard of care, compared to African American men. So overall, the use was lower across the board, but if you look at African American men, the usage was even lower. So this is definitely concerning. I call it alarming, underutilization of life-prolonging therapy in patients who are being diagnosed with newly -- or new diagnosis of metastatic prostate cancer, and we definitely can improve this. We can definitely offer better care to our patients. It is not acceptable in my view to have 30% or less patients receiving standard of care therapies. So with that, I'll go to the next study.  Greg Guthrie: Great, thanks. And this study is, “Health-related quality of life and patient-reported outcomes at final analysis of the TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen-deprivation therapy.” And you were the presenting author of this, Dr. Agarwal? Dr. Agarwal: Yes, Greg, thank you for giving the opportunity to present this study. And this is basically the continuation of the previous trial. I will not delve into in-depth analysis of these data. I just wanted to show that quality of life is not being impacted adversely by using intensified androgen deprivation therapy, so if you are using these drugs, which improves survival in a very significant fashion, and they are not being used in our patients, as we just saw in the previous study, what could be the reason? Is it the concerns about quality of life or adverse impact on quality of life? If that is the concern, this study, I think, helps refute those concerns. And in this study, which was a large study known as the TITAN trial, which led to approval of apalutamide for patients with hormone-sensitive or castration-sensitive metastatic prostate cancer and showed improved survival and radiographic progression-free and overall survival. We looked at quality of life data as reported by these patients, and these quality-of-life data were assessed by very standardized, validated scales known as FACT-P, or Functional Assessment of Cancer Therapy Prostate scale, or Brief Pain Inventory tool. And there are many other tools. So I will show you the results. And we can see here consistently there was no difference in quality of life as reported by the patients, or I would say any adverse impact on quality of life for these patients in any of these questions. As they were taking these questionnaires. So whether it was physical wellness, emotional wellness, functional well-being, social, or family, we go in and look at fatigue and there was no adverse impact on quality of life. At least from this perspective, we should not be concerned about using these drugs up front in our patients who have newly diagnosed metastatic prostate cancer.  Greg Guthrie: Great. And so what does this mean for patients?  Dr. Agarwal: From patient perspective, we can see here very clearly that using standardized tools, very validated tools, which have been used in multiple trials in the past, patients are not reporting any adverse impact on their quality of life when being treated with intensified androgen deprivation therapy. In this context, apalutamide. Greg Guthrie: Great. Alright. So let's move on to our next study, which is, “Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.” The VISION trial. Dr. Agarwal: Thank you. In my view, this is 1 of the most important studies presented in the 2021 ASCO Annual Meeting. This study was a phase 3 study where 7,000 patients were recruited, and they had metastatic castration-resistant prostate cancer and had disease progression on a prior novel hormonal therapy such as enzalutamide or abiraterone and the patients had received a taxane chemotherapy. So at least 1 taxane chemotherapy was required before the trial, and the patient had to have disease progression on a novel hormone therapy. These patients were randomized in 2 to 1 fashion to a novel drug, which is a type of radiation, intravenous radiation, as I would explain to my patients, and this is known as beta radiation. And this is a novel radiotherapy where radiation particle, which is delivering beta radiation particle to the cancer cells, is tagged to a molecule, which binds with the prostate cancer cells. So I'm simplifying it for the sake of our patients. And this particle or this compound was added to standard of care therapy and patients were randomized to standard of care therapy versus standard of care therapy plus this new compound. And standard of care therapy was a novel hormonal therapy or anything which did not include chemotherapy or radium 223, which is another type of radiation particle, but a different kind of particle known as alpha particle. So in this study, radiographic progression-free survival and overall survival were primary endpoints. We can see here that the study met both primary endpoints. There was a significant improvement in radiographic progression-free survival with an almost 5 month, 5.4 months, to be precise, improvement in radiographic progression-free survival, with a 60% reduction in risk of disease progression or death. If you look at overall survival, it was also improved in a significant fashion in patients who received the new compound known as lutetium-PSMA-617, and the median survival was improved by 4 months with an approximately 40% reduction in risk of death.  This was a well-tolerated drug overall, and if you look at hybrid side effects, treatment, and emergent side effects, there were 52.7% of patients in the experimental arm, and 38% in the control arm had those treatment-related side effects. So overall, Wwell-tolerated regimen with improved overall survival and radiographic progression. Thank you very much. Greg Guthrie: Thank you, Dr. Agarwal. This is really interesting, and it will be interesting to see if this treatment does change standard of care based on this research. Let's move on to Dr. Grivas and bladder cancer research. Let's see, so Dr. Grivas, your first study is, “Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.” And Dr. Grivas was a co-principal investigator in this trial and is senior author of the New England Journal of Medicine publication and co-author of this abstract. Go ahead, Dr. Grivas.  Dr. Grivas: Thank you so much, Greg, and thank you to Cancer.Net for the opportunity, and thanks to the audience. We welcome questions. I would like to update the audience today about the data we saw at the ASCO meeting, and I would like to place this data in context, and I would remind the audience the JAVELIN Bladder 100 trial that changed clinical practice was initially presented last year at the ASCO Virtual Meeting 2020 by Professor Powles. And this particular trial tried to answer the following question: does the immunotherapy, especially the PD-L1 inhibitor avelumab, add value in patients who completed chemotherapy in the first-line setting of metastatic urothelial cancer compared to just best supportive care in terms of longer life, in terms of overall survival, and time until the cancer grows or death, progression-free survival? This is important because until this study came about last year, the practice was, in the setting of spread metastatic urothelial cancer, when the chemotherapy stops, was we cannot give it for a long time because of potential side effects. Usually you used to wait until the cancer grows back, it progresses, or grows. So this trial compared this approach, the best supportive care, versus the immunotherapy with avelumab and the best supportive care. This particular trial, so the significant improvement of life expectancy and overall survival as well as progression-free survival, time until progression of the cancer or death, in the patients that received this immunotherapy drug avelumab as a way to maintain or sustain the benefit that is seen with chemotherapy. So we call this a maintenance therapy approach because we tried to maintain or sustain the benefit with chemotherapy. I want to highlight that this was published in the New England Journal of Medicine and the audience can retrieve that from PubMed if one wants to read the manuscript. The bottom line is this trial changed practice, and we can go now to updates. We saw this in this particular meeting, ASCO 2021, and I think the main question was, are there any particular subsets of patients, different categories of patients, who benefit more from the avelumab maintenance approach, or does this benefit all the patients? And we saw at the ASCO meeting, we saw that the benefit with this immunotherapy appears consistent across the board, across different subcategories of groups of patients. And I think that it's important to point out that we looked at patients who had what we call local disease around the bladder, that was invading this area, and the pelvic side wall that was not amenable to surgical rejection and also patients with spread of the cancer in distant sites, what we call metastasis. And we look at patients who had a primary origin in the bladder or higher up in the urinary tract, what we call kidney pelvis, or ureter, and we call this upper urinary tract, versus the lower tract, which is the bladder, and we also look at patients who had metastatic spread in the lymph nodes only or other parts of the body. And with the bottom line, we saw that the benefit with the immunotherapy was consistent across the different groups of patients. So many patients benefit from this treatment, again, with variable degrees, variable magnitude of benefit, but overall, the bottom line is, take home message is if you have clinical factors or other molecular factors, we do not have a reliable, accurate tool to select which patients should go with avelumab, so we offer it nowadays in every patient who has no contraindication to get immunotherapy and has received some disease control. Meaning a response of the cancer or stabilization of the cancer with the chemotherapy phase. So that has real clinical implications, and I encourage the audience to discuss with their oncologist about the optimal roles of immunotherapy with this maintenance setting after chemotherapy when this is controlled with chemotherapy. Just for context here, I want to highlight the options the patients have in clinical practice. And when someone is diagnosed with spread urothelial cancer, they can be offered nowadays avelumab as a maintenance strategy to maintain the benefit of chemotherapy, and the other options include immunotherapy up front, like drugs like pembrolizumab or atezolizumab, and I will come back to that question how to select your treatment in my last slide. And I want to point out these are the options, and obviously clinical trials are always a great option for patients, and they should ask their oncologist about those options. So since I talked about immunotherapy, I want to point out that the ideal chemotherapy is cisplatin-based chemotherapy. Not everybody has enough fitness of the body to tolerate cisplatin. For those patients, we think cisplatin may be too much, we use carboplatin/gemcitabine, and we use avelumab maintenance in that scenario. What about immunotherapy after that? Is there data supporting that use? And the answer is yes. There is some data suggesting that immunotherapy can be an option for some of the patients, and in this particular slide, we update the data from another clinical trial. And I will let Greg, you can read the title of that. Greg Guthrie: Sure, so this study is, “First-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial cancers response and survival results up to 5 years from the KEYNOTE-052 phase 2 study.” Dr. Grivas, you're a co-author on this study. Dr. Grivas: That's right, thank you, Greg. This trial presented longer follow up to see what happened in patients who received the immune checkpoint inhibitor anti-PD called pembrolizumab because they were not fit enough to get cisplatin chemotherapy. Keep in mind this was designed before the previous study I showed you presented the results and included patients who were not fit for cisplatin, but some of them could have been fit for carboplatin. There was no comparison here, everybody received pembrolizumab as a single agent, alone, and in this particular study, we would try to see the degree of shrinkage of the cancer and the overall response rate as well as how long people lived over time. So with longer follow-up, by the way, we published this study in the Lancet Oncology years ago, and we have longer follow-up, and what you see here is a degree of shrinkage of the cancer, what we call overall response rate, was about 29% in what we call all comers, and it was higher size of tumor shrinkage in patients with high PD-L1 expression. PD-L1 is this brake of the immune system, the checkpoint of the immune system and highly expressive measured by particular assay that pembrolizumab works better in those patients. However, some patients even with low PD-L1 measured by this CPS score I put in the slide still might have benefits, so the take-home message here is there is a particular proportion of patients who can benefit from the checkpoint inhibitor pembrolizumab. PD-L1 can be used in that setting to help decide between chemotherapy and immunotherapy. However, we have not compared directly the chemotherapy followed by the available maintenance with immunotherapy up front, so this question is still lingering. However, if the patient has a response shrinkage to pembrolizumab, many of those patients may have a long-lasting response. We tried to figure out with research how can we predict who is going to benefit more from this treatment as a matter of ongoing research. Greg Guthrie: Dr. Grivas, can you really quickly define CPS for our audience? Dr. Grivas: Absolutely. Great question. CPS is a tool we use in the pathology labs to measure the PD-L1 expression. It can be measured by different assessing antibodies, and the pathologists use a score to define if the PD-L1 is high or low. In this particular study, CPS of 10 or higher defines PD-L1 high expression, CPS below 10 defines PD-L1 low expression, and this appears to have some association with a chance of the tumor shrinking with immunotherapy with pembrolizumab. Greg Guthrie: Great. Thanks, Dr. Grivas. So our last study is, “Pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer: 5-year follow-up from the phase 3 KEYNOTE-045 trial.” Dr. Grivas Very quickly, this study compared immunotherapy, pembrolizumab, the anti-PDL1, compared to chemotherapy with paclitaxel, docetaxel, or vinflunine, the latter one is in Europe, after progression of cancer growth on platinum-based chemotherapy. This was published in the New England Journal of Medicine a few years ago, and pembrolizumab prolonged survival, people lived longer compared to the chemotherapy. And this longer follow-up presented by Dr. Bellmunt and colleagues, showed the sustained results with follow-up, this population of patients had already received cisplatin-based chemotherapy and the cancer progressed, growth, despite that chemo, and in those patients, pembrolizumab appears to produce better results compared to this salvage chemotherapy shown in that slide. And this has implications because immunotherapy can be used in those patients after progression on platinum-based chemotherapy. And just to wrap up here the discussion, I just want to give the options to the patients, see if someone has a new urothelial cancer, options include cisplatin/gemcitabine, or if someone is not fit enough for cisplatin, carboplatin/gemcitabine, and both of those scenarios can be followed by avelumab, and those with shrinking or stable disease, patients who have progression on platinum-based chemotherapy can get pembrolizumab and of course other options available. We can go into another podcast, and I encourage the audience to look and discuss with their oncologist about those options, and the take home message, the clinical trials is what got us here, and I recommend clinical trials to be discussed with your oncologist. Thank you so much, and I'll be happy to take questions.  Greg Guthrie: Thanks, Dr. Grivas. So we're going to move on to Dr. Zhang, who is going to talk about kidney cancer. So our first study today is, “Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: a randomized, double-blind, phase III KEYNOTE-564 study.” Dr. Zhang: Thanks, Greg. I'm really excited to be here today and thanks, everyone, for joining. KEYNOTE-564 was presented at the ASCO plenary by our colleague Dr. Toni K. Choueiri, and this is a highly anticipated study in the adjuvant space for kidney cancer and enrolled patients with high-risk clear cell kidney cancer who had undergone either nephrectomy or a metastastectomy, removing their few sites of metastatic disease and treating those patients with either pembrolizumab for up to a year or placebo. And the endpoint was disease-free survival, and enough events had occurred by this ASCO for us to see the primary results. So the overall -- the study was positive. For the primary endpoint, disease-free survival improvement was met with a hazard ratio of 0.68 and the estimated disease-free survival rate at 2 years was 77% for patients treated with pembrolizumab versus 68% for patients treated with placebo. The overall survival favored pembrolizumab, but it was not yet statistically significant, and follow-up will be needed. Overall, we see an improvement in disease-free survival delaying time until recurrence for patients treated with pembrolizumab, and this was the first study in this adjuvant space showing checkpoint inhibition has a role in adjuvant treatment of renal cell carcinoma.  Greg Guthrie: Thanks, Dr. Zhang. Our next study is, “Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: results from 42-month follow-up of KEYNOTE-426.” Dr. Zhang: This study, KEYNOTE-426, we are all very familiar with. Pembrolizumab and axitinib has been used for the last 2 years in the first-line treatment of clear cell metastatic kidney cell cancer, and it's a longer-term follow-up, more events and more understanding of what happens to these patients once they're treated in a longer term, so primary endpoints of course of this phase 3 study were progression-free survival and overall survival. When we're looking at this medium duration of follow-up at 42 months, so about 3 and a half years, pembrolizumab and axitinib improved both median overall survival as well as median progression-free survival. We'd point out that the -- at the 3 and a half year mark, the overall survival rate for patients treated with the combination was about 57.5%. And the progression-free survival rate was about 25%, so about a third of patients had not had progression of disease at 3 and a half years. Which is quite meaningful if they can stay on their first-line treatment for that long. The objective response was 60%, and of note, the complete response rate had been updated to about 10%. So there are some patients that do have delayed complete responses. And no new safety signals were observed. So overall, certainly still provides a lot of evidence to treat with pembrolizumab and axitinib for patients in the front-line setting. Greg Guthrie: Great. And our last study here is, “Health-related quality of life analysis from the phase 3 CLEAR trial of lenvatinib plus pembrolizumab or everolimus versus sunitinib for patients with advanced renal cell carcinoma.” Dr. Zhang: This was the phase III trial in first-line treatment of metastatic clear cell kidney cancer that was reported at GU ASCO in February of 2020, and it was a 3-arm randomization to lenvatinib with everolimus in the standard study, and lenvatinib with pembrolizumab or sunitinib alone, and we saw the efficacy data in February, and here we're seeing the quality of life outcomes, and looking at how patients are doing, patient-reported outcomes on these treatments. And so with multiple quality of life measures, we're seeing improvements in patients that had better disease-related scores of symptoms when treated with lenvatinib and pembrolizumab versus sunitinib. We're seeing pain scores improve and patients having less diarrhea, appetite loss, when we're comparing against sunitinib. Of note, it's hard to specifically tie a particular symptom, if that's improved, because they've had better disease control or if it's more from the treatment side effect itself. So still hard to tease out a causality in these quality of life measures, but overall, improvement in patients' quality of life when treated with lenvatinib and pembrolizumab. And certainly provides some more data for patients receiving this combination. And so I just wanted to highlight our ongoing phase 3 combination trials and first-line metastatic kidney cancer. PIVOT-09 with bempegaldesleukin has completed accrual in the first triplet of COSMIC-313 with ipilimumab, nivolumab and cabozantinib has completed accrual, so the actively enrolling studies currently are PEDIGREE and PROBE. These are studies that are being carried out in the cancer cooperative groups, as well as a triplet belzutifan lenvatinib with pembrolizumab, a study that Merck is running and all 3 very important studies we will continue to learn from and answer some important, clinically relevant sequencing treatment discontinuation, nephrectomy side effect questions. Thanks to everybody. Greg Guthrie: We have 1 more. So, “Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.” Dr. Zhang: Dr. Rodriguez from Spain presented this of papillary renal cell carcinoma treated with savolitinib and durvalumab, and specifically looked at the MET-driven subset of 14 patients out of these 42 patients. The efficacy primary end point was objective response rate. And of note, and median progression-free survival for the 42 patients who were all treated, it was 4.9 months and in MET-driven disease, so savolitinib targets MET, so MET-driven disease was 10.5 months and the median overall survival in everyone was 14 months, versus MET-driven was 27 months, and also higher response rates for patients with MET-driven disease. So I think personally, hypothesis generating, we will likely be seeing more trials with durvalumab and savolitinib in MET-driven papillary renal cell carcinoma. Greg Guthrie: Thank you, again, Dr. Zhang. And Dr. Gilligan, we're going to talk about some testicular cancer research now, and the first study is, “Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort.” Dr. Gilligan: So this study was looking at what happens with testicular cancer patients who are cured of their cancer, are they at risk of dying of other causes? They looked at over 5,000 men treated between 1980 and 2009, so it's important to recognize that some of the treatments given back then are a little different than the way they're given now. And it looked at the risk of death from causes other than testis cancer compared to men without testicular cancer in the general population, and the concerning finding from this study, and it's not the first study to report this, was that the risk of non-testicular cancer death, that is, death from other causes, was increased by about 28% in men who had been treated with radiation therapy and about 23% in men treated with chemotherapy. There's a risk of non-testicular cancer death, the risk, excuse me, was doubled in those whose treatment included both. So it was higher with either radiation or chemo and it was actually 100% higher or double than both those who had chemotherapy and radiation. As you got more chemotherapy, the risk went up. There was no trend towards the increase with just 1 or 2 cycles. We started to see the increase with 3 cycles, and it became statistically significant with 4 cycles. But there wasn't much difference between 3 and 4 in terms of the absolute number that was seen. In terms of death from other cancers, so why is this happening? Other cancers are a major issue after chemotherapy or radiation. Again, the risk was increased 60% after radiation therapy and 43% after chemotherapy, and those who got both, the risk of cancer was 3 times higher than the general population. So that's in men who had chemotherapy plus radiation therapy. Fortunately, there are not a lot of men who get both of those treatments anymore. Non-cancer deaths increased 17% after chemo and 55% of treatment included both. So the risk for non-cancer deaths was not as high as the risk for death from secondary malignancies. Interestingly, the risk of suicide increased 63% in men treated with chemotherapy. That's not affecting as many men as those other numbers, even though 63% number looks high, but it is a concern. Those treated only with surgery did not have an increased risk of non-testicular cancer death. What does this mean for patients? It really means when we can use surgical treatments instead of chemotherapy or radiation as an additional incentive to try do that, and what that may mean is there should be a larger role for retroperitoneal lymph node dissection as an alternative to chemotherapy or radiation therapy. Secondly, for patients getting chemotherapy, it's important to minimize the number of cycles of chemo as long as we're not sacrificing long-term cure rates, because the biggest risk of death is dying from the cancer, but that means limiting to the 3 cycles instead of 4 cycles is probably a good idea, and I think it's an argument to use 3 cycles of BPE instead of 4 cycles of EP because it's really the etoposide and the cisplatin that is linked to the secondary cancer risk, not the bleomycin, as far as we know. And then lastly, we need to pay attention to the mental health needs of men treated with chemotherapy. That there is more emotional distress and we're seeing here a higher risk of suicide.  Greg Guthrie: So our second trial is the, “SEMS trial: result of a prospective multi-institutional phase 2 clinical trial of surgery in early metastatic seminoma.” Dr. Gilligan: So if we're going to use more retroperitoneal dissection and less chemotherapy or radiation, 1 place to do that is in stage 1 and stage 2 seminoma, and many centers around the country have started doing that, and this was a trial that looked at that approach. So these are men who normally would be treated with chemotherapy, 3 cycles of BEP, or radiation therapy to the back of the abdomen and part of the pelvis potentially. This study looked at the small number of patients, 55 men, low volume, stage 2 seminoma up to 3 centimeters of size and maximum dimension. And what they reported of those men undergoing retroperitoneal lymph node dissection, 10 relapsed, so 18% relapsed after median follow-up of 24 months, they were all alive at the end of the study. No deaths. 8 of 10 relapses were treated with chemotherapy, and 2 were treated with additional [surgery]. Out of the 55 men, 8 ended up getting chemotherapy. Normally, all of them would have gotten either chemo or radiation. Relapse-free survival was 87%, overall survival was 100%. Seven (7) patients developed complications after RPLND and 5 of them were mild. Two (2) were more severe. So it's a well-tolerated treatment, if it's done at a large volume center, it's worth noting that the centers participating in the study were large volume centers. Again, if not treated with RPLND, all of these men would have gotten chemo or radiation. The relapse rate after chemotherapy or radiation is about 5%. So the relapse risk is higher after surgery, but in the sense, if we take 100 men with early stage 2 seminoma and do an RPLND instead of chemo or radiation, we can spare 80% of them the long-term effects of chemotherapy or radiation. Alternatively, if the priority is simply to prevent a relapse, radiation therapy and chemotherapy are more effective at that, the relapse risk being 5% but at the cost of long-term side effects from chemotherapy or radiation. Bottom line there is an additional treatment option for low volume stage 2 seminoma for men who prioritize avoiding the complications of chemotherapy or radiation therapy. Both of which are associated with an increased risk of death from other causes. The price we pay for that is the relapse risk is higher with RPLND compared to the other approaches. Not all centers are going to be offering this, but major centers that do a lot of testicular cancer, this is becoming a new treatment option. With the caveat that we have less experience with this approach. This is a relatively small study. And we have a lot more experience with chemotherapy or radiation. I don't think there's a one size fits all here, but I think patients should talk about it with their doctor. If they have early-stage seminoma, they should talk about surgery as an alternative to radiation or chemo. Greg Guthrie: Here we go. “Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor.” Dr. Gilligan: So this study is looking at the question, if you take a man who has retroperitoneal lymph nodes that are enlarged and metastatic non-seminomatous testis cancer with lymphadenopathy in the back of the abdomen and you put them through chemotherapy and at the end, all retroperitoneal nodes are now within normal limits, normal size nodes, and no bigger than 10 millimeters or 1 centimeter, do we need to do a retroperitoneal lymph node dissection on those patients? Some centers recommend it and some don't. This looked at 388 men in that situation. They were put on surveillance. These men did not undergo the post-chemo RPLND. Two years survival, overall survival was 97.8%. Two-year progression-free survival was at 90%, 34 patients relapsed, and 10 of the men died. Men who did relapse had surgery, chemotherapy, or both as subsequent treatment. There's a prior similar study that was multicenter that had longer follow-up of 5 years, and they reported of ;161 men who had a complete response to the first-line chemo, 10 relapsed (that's 6%) and none died. If we combine these 2 studies together, the bottom line is you would have to perform a post-chemotherapy retroperitoneal dissection, which is a big operation, on about 550 men to prevent potentially at most 44 relapses and 10 deaths. We don't know if we would prevent or how many of those relapses and deaths we would prevent. But there's a lot of operations with a relatively low yield. In the future, we hope to have blood tests that will tell us which men need surgery. And even right now, we're close to the point that we have blood tests that will detect residual cancer. And the chance is we worry about residual cancer in these patients and we don't have the blood test to pick it up. But the bottom line is in the meantime, the preferred management strategy is surveillance rather than surgery for most men. There's some men for whom RPLND may make sense in the center in this setting and some centers that will probably continue to recommend it for most men. I think this data really casts doubt on whether we ought to be doing this operation in these men as a routine practice as opposed to an exceptional practice for men who have particular characteristics. Thank you. Greg Guthrie: Thank you, Dr. Gilligan. And now we can move on to answering some questions. What is the average time expected to see a decline in PSA in patients treated with lutetium-177 PSMA? Dr. Agarwal: I think this a great question and I think we're waiting for the manuscript published to go through the nuances of those data. Right now, what Dr. Michael Morris from Memorial Sloane-Kettering presented were the high-level data on pre-survival and overall survival and some secondary endpoints. We are anxiously waiting the full data in the form of a manuscript. And until then, I will not be able to answer that question. I would like to add that usually the median time, if you look at how -- for how long patients were receiving lutetium, it was 5 to 6 months. If I -- if my recollection is correct. Greg Guthrie: Is radiation required prior to initiating chemo if there's tumor presence? And Dr. Gilligan, you responded. “We rarely use radiation therapy for testicular cancer at this time. Sometimes it is used for stage 1 or stage 2 seminoma as primary treatment instead of chemotherapy.” And I'll just read these aloud for our viewers here. If a patient has both prostate and bladder cancer, how do you decide which therapy should take priority, also, is the CPS typically included on the biopsy report? And Dr. Grivas, you responded, which I'll read here. “This is a bit of a complicated scenario that requires detailed discussion with a urologist and medical oncologist. Regarding CPS, the possible role is only in the first-line setting of metastatic disease to help somewhat decide between chemotherapy followed by avelumab maintenance and immunotherapy. However, it's not a perfect biomarker and not part of the pathology report, it's a special test that requires specific ordering.” I have a question for you, Dr. Zhang. Why do combination treatments seem to work better in kidney cancer? Wouldn't you have more side effects because you're taking 2 drugs at the same time? Dr. Zhang: It's an interesting question. You know, our immunotherapy backbones seem to have good treatment benefit for these immune responsive diseases. The VEGF inhibitors that blocked blood vessel formation for many of our patients with clear cell kidney cancer, they tend to have an immunomodulatory role, so if we normalize blood vessels in the tumor microenvironment, the thought is that the T cells and immune cells can actually get into that space more readily. And so many of these blood vessel blockers are hypothesized to have increased immunomodulatory times of behaviors and the combination actually can be more effective than either agent alone, and we've certainly seen that in practice and really excited to see these combination strategies thrive and be standard of care for our patients now and first-line treatment. For the side effect question, you know, I do think that sometimes we do have to tease out which of the side effects is related to the oral treatment, the blood vessel blocker versus the immune therapy. But it's often experienced oncologists who are able to manage these side effects. We can try to tailor and see which of the side effects is due to which treatment and how to reduce or hold treatments when necessary. Greg Guthrie: Great. I just got a follow-up question for you, Dr. Zhang. Are there any studies for papillary type kidney cancer with sarcoma? Dr. Zhang: I would assume you're asking about sarcomatoid renal cell carcinoma within papillary, so for papillary type of kidney cancers, there are ongoing studies. For example, with FH mutations and FMH loss. For sarcomatoid disease, this is a special type of histology that can occur with any of our actual histologies of kidney cancer. And we know from our phase 3 trials in clear cell sarcomatoid renal cells that these tend to respond to the immunotherapy combinations. And so I would urge using an immune therapy combination in patients who had sarcomatoid renal cell carcinoma. Greg Guthrie: Dr. Agarwal, here is a question for you. There were several studies in here that showed many patients did not receive combination ADT with other novel therapies, which you describe as the standard of care, including the one you discussed. Is this something that patients should proactively bring up with their doctors? Dr. Agarwal: Fantastic question. I'm so glad you asked. The answer is yes: It is our responsibility as physicians and providers, but it doesn't hurt if our patients are educated and challenge us in our decision-making. It is a shared decision-making, it is not the doctor's decision. In my view, it's the patient's decision with help from the doctors. So, yes, please go do it. Doctors usually welcome that. Greg Guthrie: Great. Dr. Grivas: I see one for Dr. Gilligan about surveillance imaging that just popped up. [Is there any data on the benefits vs. risks for imaging based surveillance (CT, MRI, none) for longer-term follow-up periods (e.g. 2+ years)?] Dr. Gilligan: Yeah, they're asking whether there's data on benefit versus risk for imaging-based surveillance and it's actually a very timely question in the sense that we're starting to get data that MRI is very accurate for this. And may likely become a substitute for CT scans at some point in the future. This is something we talk about a lot in terms of surveillance for testicular cancer patients, can we switch to MRI from CT because CT has ionization that can cause other cancers, and MRI does not. The good news is it looks like with current CT scanning, which is lower dose than older CT scanning, the risk of cancer from the CT scan seems really miniscule. Ultimately, it would be great to get it down to 0 and not do them, but we're still doing them. The switch to MRI is being held up by the fact that when you go in and get an imaging study for surveillance, your scans get looked at by a radiologist and also by the oncologist and all of us who do a lot of testicular cancer have multiple stories of catching stuff that the radiologist missed, and they also catch stuff that we miss. It goes both directions, and we're having 2 different people read the films to get a more accurate read. With MRI, most oncologists are not competent to read an MRI well and some radiologists are not great, and the centers where they have excellence have shown that MRIs are just as good as CT scans if read by fully qualified people. And the concern is: are they going to be skillfully read? So the switch to MRI will happen in the future, and I have spoken with people very recently about this that are practicing around the country and the people I talked to were not ready to make the switch because of the concern that stuff might get missed. And I think we can be reassured with the modern lower-dose CT scans, the risk seems to be quite small, and I look forward in the future to making that switch at some point.  Greg Guthrie: And I think that's going to be our last question this afternoon. Thank you to all our participants for sharing this great research with us, as well as your expertise, it's been a real pleasure on this live webinar here. ASCO: Thank you Dr. Agarwal, Dr. Grivas, Dr. Zhang, and Dr. Gilligan.  You can find more research from recent scientific meetings at www.cancer.net. And if this podcast was useful, please take a minute to subscribe, rate, and review the show wherever you listen to podcasts. This Cancer.Net podcast is part of the ASCO Podcast Network. This collection of 9 programs offers insight into the world of cancer care, covering a range of educational, inspirational, and scientific content. You can find all 9 shows, including this one, at podcast.asco.org. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/donate. This presentation is provided solely for informational purposes. The ideas and opinions expressed in this presentation do not necessarily reflect the views of the American Society of Clinical Oncology (ASCO) or its affiliates. The mention of any product, service, or therapy in this presentation should not be construed as an endorsement of any product, service, or therapy mentioned. The information herein does not constitute medical or legal advice, and is not intended for use in the diagnosis or treatment of individual conditions or as a substitute for consultation with a licensed medical professional. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the presentation or any errors or omissions. © ASCO 2021, all rights reserved.

My guest today is Juney Ham, co-founder and CEO of Beacon. He was previously an executive at Expedia and Airbnb, and CMO of Hired.com. This is Part 2 dive into the Hired.com business.You can also listen to these interviews in your podcast player of choice: Apple, Sticher, TuneIn, Overcast , Spotify. Private Feed (for premium episodes).TranscriptEdward: This is part two of my interview with Juney Ham. Today, we're going to dive into his experience as CMO of Hired. Juney, can you start by explaining what Hired does?Juney: Hired is a talent marketplace where vetted engineers, product managers, designers, and other professionals can connect with in demand companies that are actively seeking great candidates for their open roles. Hired built the technology platform that allows candidates and clients to connect and interact with each other directly through the system, which also creates more efficiency and transparency throughout the process.Edward: How is that different from every other recruiting organization out there? Everything from monster.com to our local regional recruiting agency that can find a developer for you?Juney: It's a great question. Hired is, first and foremost, a marketplace which is one of the first times that a marketplace paradigm was used both in terms of the value proposition for attendants and clients, as well as the positioning in the market whether that's Monster or a boutique recruiting agency. Hired also pioneered some of the more interesting aspects to the model when they first launched—having companies actually request interviews or pitch the candidate, versus candidates generally entering a company for the interview process. Also to provide salary transparency upfront which is, I'd say, something that still doesn't happen that frequently outside of platforms like Hired. It's interesting, before Hired rebranded, the company was called DeveloperAuction. The salary transparency was actually structured like companies competing for candidates and bidding on them. Candidates would see who was offering the most before deciding who they wanted to interview with. Base salary was an important component to how a candidate would prioritize the opportunity that these various companies were offering. Given that the company was first focused on rails engineers in San Francisco during a time when rails engineers in San Francisco were some of the most in demand roles in all of the startup ecosystem, this made a lot of sense given the supply constraint nature of the market at that time. We also supported candidates. We got a team called talent advocates. They partnered and supported candidates with everything, from navigating the platform, to providing interview best practices, mock interviews, and overall career guidance. It's something that is happening more frequently now. I would say that there are a new crop of companies providing these kinds of services to candidates directly today. It was one of the first times a company that was primarily being paid for and incentivized by clients provide amounts of free service to candidates. I just thought that that was really interesting. The model is one where Hired had the flexibility to be able to do that.Edward: Is it not then a monster.com or indeed.com with additional services layered on? You said that it's a marketplace whereas Monster isn't. Why don't you consider Monster or Indeed a marketplace?Juney: Monster and Indeed are job boards. They're places where companies put their job descriptions. It's a static experience. Hired in terms of the marketplace, we were constantly calibrating the volume of candidates and clients that interact within the space. There was a qualification layer that happened. It allowed for us, being Hired, a little bit more control over ensuring that the overall interaction quality was high. Whereas a job board like Monster, anybody and everybody can put a post on the job board. Depending on the role, location, all these things—for sure, we'd have a vastly different experience if you have 5000 jobs of which many of them aren't really qualified or vetted from a job description quality standpoint, or are these roles actually what they say they're representing. There's a lot of that work that happened within the marketplace for Hired. I think that's one of the key differences between a job board paradigm and a marketplace paradigm. Edward: You do qualification on both sides, right? You're making sure both the candidates are good enough before they can apply, and that the jobs are good enough before they're allowed to be posted.Juney: That's right. I would say that in a world where supply and demand are equally calibrated, you would do roughly the same amount of qualification on both sides, but for Hired—especially during the time that I was there—the market was broadly supply-constrained and yet we wanted to make sure that the quality of the candidates' really high and was reflective of the roles that were available on the platform. There's a lot of vetting that we did on the candidate side and it involves something that we positioned to the market. It was one of the reasons why companies came to us—because they felt that we were doing a lot of that pre-qualification upfront. Therefore, the candidates that were on the platform that they were seeing, there was confidence that those candidates were going to be the right fit for the roles.Edward: That was my next question. Where is the limiting factor? Was the limiting factor in finding qualified candidates, or is the limiting factor in finding qualified jobs for those candidates?Juney: It was more on the candidate side to be fair. We did a pretty good job of fueling the top of the funnel. It fueled around the total population test that we thought would be a good fit. Because qualification was done both for the skills, experience, and the tenure of the candidates that were in those relevant roles—and ultimately the role that they were looking for in the next step in their career—it was also what types of skills. At that time, the geographic component was also very important. Remote is obviously an important factor today but not as much a factor then. The alignment between the candidates, where they were located, what they were looking for, and ultimately, what roles were available in the platform were also factors in how to think about which candidates would be introduced to the platform. Our qualification criteria was such that, about 5%–10% of the candidates were approved, which means 90%–95% of the candidates were rejected from the platform. Even though from a candidate acquisition standpoint instead of the marketing standpoint we're bringing a wide variety of candidates into the organization and into the funnel, we're only able to surface about 5%–10% of those candidates that are in there at the time. It was definitely a supply challenge for us.Edward: Your monetization effectively was every time you place a candidate at a job, that company would pay you.Juney: Originally, yes. The model was transactional. As you describe it, any time a role was filled, the company would pay a percentage of salary as a fee. Over time, as we were also working with more midmarket—and then ultimately enterprise companies—we had played with different models as well. There's also a subscription model. There were base pay type models as well that we experimented with. Over time, the shift in revenue became less on the transactional side and more on the subscription side.Edward: Even so, even on the subscription side, the company's effectively paying for placements. If you're not getting them placements, they're not going to renew the subscription.Juney: That's correct.Edward: You're collecting all these candidates. Out of 100 candidates, you collect only 5 or 10 of them you're putting in front of companies. What do you do with the other 90 people? Is there any way to monetize that exhaust, or is it just gone?Juney: This is a really great question and one of the challenges that I was addressing over a long period of time in Hired. A combination of things were experimented on and then things that we executed against. One is, as I was saying before, there are a variety of factors as to why a candidate wouldn't enter the marketplace. Some of those are due to a candidate's specific components, others are related to the client's specific components. Some of those things change every time. What we started to build was a way to nurture all of these candidates that might not have been the right fit for the platform at the time, but that we believe in the future—or as the client ecosystem of opportunity is changed—that they would be. There was this long-term candidate nurturing paradigm that we were building to ensure that candidates that did unfortunately not qualify still had an opportunity to be qualified in the future. That was the big component to it. The other was, the challenge with what we were doing was that if they were not qualified today, there's definitely a chance that they could be qualified next month. Beyond just overall nurturing to ensure that we were top of line in a world where if they're looking for something else, the Hired brand is still a positive experience for them even if they weren't qualified, the other piece was ensuring that as we were seeing the opportunities within the platform change, we had a mechanism to pool those candidates, even if they weren't qualified in the traditional sense to be able to qualify them down the stream. There are a number of different ways to actually reach out to them for specific opportunities that were specific to their experiences and what the client needed. Edward: Where did you find the candidates? What marketing channels did you use to go and get these hundreds, thousands, and tens of thousands of candidates to go and apply?Juney: We did a lot of performance marketing around Google, LinkedIn, Facebook, a lot of the standard search in the marketing and paid social channels. Edward: These are people who are looking for jobs. Someone who says, I'm looking for a developer job, and Hired effectively becomes a distribution place, almost like getting the shelf space on search for when someone's searching for a job, you want to be in their face.Juney: That's right. For the roles that we were working with companies on, we are definitely focused on search. Making sure that if somebody is looking for an opportunity—rails engineers in San Francisco—we would be there. Then, we would bring them onto the onboarding experience, and then once we've gotten their information, then we will qualify them or not. In those situations generally, it's a higher degree of confidence that they were qualified.Edward: In a situation like that, you're competing against every other recruiting organization out there. How do you win at auction? Do you monetize better than those other options because you're more bespoke?Juney: A number of our features and the things that we called out in our experience were interesting to candidates. Therefore, whether you are competing with every legacy or modern competitor, Hired had a number of things going for it.One was the Hired brand was actually really well-regarded in the technology ecosystem data companies. The fact that we had "the best companies" competing for your attention within our marketplace was definitely a strong selling point for candidates. As well as the fact that they could work with the talent advocate, the fact that companies actually shared offer details before you even interview with them, makes it such that the experience itself was different for them.Beyond the fact that we did what we can to be excellent within the operations of managing these channels, some of these value propositions were definitely additive to being able to convince them to apply for the platform.Edward: It's interesting. When it comes to these marketplaces, effectively, by making it more attractive for the consumer side of the marketplace—or in this case, the employee side of the marketplace—you can better attract candidates, which then lets you get more leverage towards attracting the strongest employer side or the strongest B2B side, which then gives you an advantage in attracting more of the best employees because you have the best employers.Juney: That's exactly right. We actually hired a lot of our engineers off the platform ourselves. We participated as a client in our own marketplace. It was interesting to be able to do that because it also provided a really great candid experience for those incoming employees. It connects this idea that our mission externally—which was to transform how hiring works—was something that's basal internally in practice. It's a fantastic employer branding opportunity.Edward: Roughly what percentage of your placed candidates are coming in through either paid search or organic search, through direct search? Juney: Paid search and organic search? That number actually changes a lot over time, but I would say, it was a good quarter to a third percent, or 25%–33%. The rest were a combination of direct type-in and other kinds of referral channels. We had a pretty strong referral program on the candidate side. That was leveraged a lot from our existing candidates that participated in the marketplace. It was a pretty significant percentage, but not the majority.Edward: It's interesting though. If you say that the significant percentage is coming in through direct type-in, or coming in through referrals with existing employees, you have to get existing employees first before you can get the referrals to happen from them. Are the knock-on effects of the paid search 2X, the 25%, is it close to the 50%?Juney: I would say earlier on in the tenure of the company, the number of SEMs and SEOs representative samples of the total population of candidates decreased over time. In the beginning it was 40%, 50%, 60%, because that's how we were actually building the marketplace initially. To your point, I think there were knock-on effects, but it's also an example of how as the company scaled, and as the population matured, both on the candidate side and the client side really, that these other channels started to bring in value because we were actually continuously engaging this community. For example, the referral component increased significantly over time. In the beginning obviously, with the first cohorts, that channel's not existing, so a much higher percentage of our candidates came from SEM primarily. Over time it was SEO, but as the company started to mature, that number hovered up like that, 25%—35%.Edward: Apart from referrals, direct type-in, and some that are naturally going to come towards you, what were the other outreach channels that you used that were effective? How is paid social?Juney: We did paid social as well. It was effective as well, but there were different components around paid social that were advantages as well as disadvantages. I think the overall volume adds that we had were higher but the qualification rate was lower. Edward: When you say qualification rate, there's different reasons why they're not qualified. Were they not qualified because they weren't good? Because they didn't have the skills, or they were not qualified because they weren't really actually ready to take a job? Juney: It was a combination of candidates that were not qualified because maybe they were too early on in their career, or they would be in markets that we haven't launched in yet. For example with Facebook ads, we have a lot of candidates that just weren't qualified due to the fact that we didn't have the marketplace active there, or we didn't have roles that were specifically for the skills that they have. Think about engineering as just one example. You could think about the hierarchy of roles that are associated with being a software engineer. You could be a product engineer, full stack, it could be back-end, it could be data.There are all these different elements around the role itself that subdivided into more specific categories. It could just be that there's misalignment around that person's skill set and all of the roles that we had available. Quality is not a perfect word here but quality as it relates to the candidate's experience or what they bring to the table, it's in the candidate's overall representation in the client-side and whether we have roles for them.Edward: That's interesting. That feels like that's a problem solvable with better targeting. Is it just that at paid social you couldn't target effectively enough to go and find the people that were the ruby on rails developers in San Francisco, Berkeley area?Juney: At that time, I would argue that targeting has massively improved as Facebook's platform has evolved and matured. Also, think about this. A candidate that is being marketed to for rails engineer—they might actually have some rails experience, but have never actually developed in an engineering organization for that technology, or have done different things around it. It's not super clear whether you're targeting them or whether that person that is being targeted to actually, correctly represents their experience. Some of that filtering and that qualification is a lot more nuance once they actually apply for the marketplace. We have to get through thousands of conversations. Part of that qualification is the majority of those candidates that were qualifying would actually have some set of interactions with the teams internally to determine if they were qualified or not. Some of that information you can't really pull until you have that conversation.Edward: How about podcasts? How did the podcast work for you?Juney: Podcasts are really effective for us. It's interesting because there is obviously a vibrant community of creators, podcasts, particularly like engineering, software development, and startups. Podcasts work awesome for us. They work really well. Over time, we became pretty competitive and just locking up inventory to be able to have a consistent podcast strategy became tougher over time. I would say that one of the main challenges is that there's no infinite inventory of podcasts that are highly relevant to the audience that we're going after. That was the main challenge around the podcast. There was more about ensuring that we have enough inventory. There's a consistent approach to being able to not be out bid, or basically ensuring that we can continue to advertise on podcasts. That was the major issue for us, but overall as a channel, podcasts are really effective.Edward: If feels like that's kind of the issue across the board. Effectively, you ran out of inventory. There's only so many people searching for ruby on rails, developer jobs in San Francisco on paid search or on SEO. There's only so many people listening to a podcast about how to be a better ruby on rails developer. Do you eventually just hit them initial returns and now you need to go on branching the other products?  Juney: It's interesting that you bring that up. I wouldn't say we directly address that problem or that challenge during the arc of Hired's growth. Hired initially had a very aggressive stance towards expansion. Not too long after they started, we were expanding into different types of engineering categories. We started out with rails engineers. They were all engineers. Then, we went to the product vendors. Then, we went to the designers. We actually piloted and launched marketplaces for salespeople and marketers too. Starting from San Francisco, we launched New York, London, and Paris. We launched Chicago, Toronto, we launched a variety of markets. On a per market cohort basis, we definitely ran into head wins as we thought about both scale and efficiency over a company-growth standpoint. The focus was to continue to launch new markets, categories, and new geographies. I would not say it directly solves the problem that you're bringing up at all. But it was a different sort of challenges that we needed to also tackle which was, how do we ensure that for every market we're launching, we're actively launching and scaling those channels right out of the gate to ensure that the marketplace has the critical mass of candidates and clients to be able to work and be effective for that market.The biggest things that we saw were each channel—when we launched each marketplace—had different levels of effectiveness. It was really a matter of calibrating all the different channels that we had under disposal to calibrate the market. The other thing to note here is it wasn't that we were trying to massively grow candidates and massively grow clients and that this was this infinite inventory and do whatever you can to drive as many candidates to the marketplace as possible. There was this constant calibration where we want to ensure that if we have a lot of clients on the platform representing a number of roles, that number actually did fit in into how many candidates we ultimately want to bring on to the platform. It wasn't so much that it was everything at breakneck speed all the time. There was this bit of information that was being passed between the two sets of marketplace to ensure how much do we want to grow our overall candidate population based on what roles we had on the client-side.Edward: Juney, this has been fantastic. Before you go, talk to me about your quake book and how it changed your way of thinking about the world.Juney: My quake book is The Hard Thing About Hard Things by Ben Horowitz. I remember reading it the first time. I read it essentially cover to cover in one, maybe two sittings. The thing that was so poignant for me was that the problems that founders, entrepreneurs and executives go through are the kinds of problems that I had seen as a founder myself but didn't really see out in space. These were problems that people weren't comfortably talking about. Sharing issues, challenges, and problems that you had gone through as a founder or as an executive were not things that you did. It wasn't really celebrated. The book really helped me understand that people, even with Ben's stature, had gone through a lot of these challenges and had to struggle through these problems. The lessons you learned across every aspect of being a leader were lessons that you learned ultimately but also through a lot of failures. For me, it helped me understand that as an aspiring founder or leader that I will get to the other side. It could be that I will encounter many failures, many hard lessons, and challenges but getting through that was almost like what you earned—the currency that you earned to be able to then continue to grow and move forward. For me, that was the most important thing which is making everything a lot more real and ensuring that I didn't have to project this aura of perfection or this ability to solve any problem through sheer intelligence alone. It was that a lot of this is falling on your face and stubbing your toe. The act of falling in your face and the act of stabbing your toe actually is what drives you to learn those lessons and be better over time.Edward: Juney, this has been fantastic. Thank you so much for your time today.Juney: Thanks, Ed. I had a really good time as well, I appreciate it. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit marketingbs.substack.com

Neste episódio, Dr. Daniel Vargas, oncologista clínico do Grupo Oncoclínicas de Brasília, apresenta os highlights da ASCO GU 2021 na área de Tumores de Testículo. O primeiro trabalho comentado é o estudo fase III TRISST, que avaliou o intervalo ideal entre os exames de imagem e o melhor método a ser utilizado como seguimento (Tomografia computadorizada versus Ressonância Nuclear Magnética) em pacientes com seminoma estádio I submetidos à orquiectomia, com o objetivo de evitar a exposição à radiação ionizante, liberada pela tomografia. O segundo estudo (SEMS), observou o uso de linfadenopatia retroperitoneal modificada como tratamento de primeira linha para pacientes com seminoma estádio I e estádio IIA ou IIB, população classicamente tratada com radioterapia ou quimioterapia sistêmica, ambos os tratamentos com potencial de efeitos adversos importantes. O terceiro estudo em destaque avaliou o uso de microRNA-371 circulante (miR371) como método diagnóstico para tumores de testículo avançado. Dados preliminares do estudo haviam sido publicados do Journal of Clinical Oncology em 2019. Os resultados atualizados demonstraram o potencial dessa metodologia. Confira o episódio e entenda o desenho dos estudos.

Google says a lot of things. Sometimes the search engine's spokespersons are incredibly transparent and sometimes they're bizarrely opaque. Sometimes they contradict each other and sometimes the effects of technologies being innovated on the far side of the Googleplex aren't as well known by their spokespersons around the world. Today Jim and Dave discuss a number of things Google's said in the last week that directly contradict things they told webmasters previously, focusing on core-update recoveries and the importance of core web vitals as potential or future ranking signals. We also talk about a terrible case of negative SEO, the Change.org petition for Google to restore hidden search term data for SEMs, and congratulate John Mueller for being named Search Personality of the Year. We also noted the panel hosted by Ginny Marvin, “The SEO Gender Gap and How to Close It”, being held online, Sept. 11, 2020.

Google says a lot of things. Sometimes the search engine’s spokespersons are incredibly transparent and sometimes they’re bizarrely opaque. Sometimes they contradict each other and sometimes the effects of technologies being innovated on the far side of the Googleplex aren’t as well known by their spokespersons around the world. Today Jim and Dave discuss a number of things Google’s said in the last week that directly contradict things they told webmasters previously, focusing on core-update recoveries and the importance of core web vitals as potential or future ranking signals. We also talk about a terrible case of negative SEO, the Change.org petition for Google to restore hidden search term data for SEMs, and congratulate John Mueller for being named Search Personality of the Year. We also noted the panel hosted by Ginny Marvin, “The SEO Gender Gap and How to Close It”, being held online, Sept. 11, 2020.

Show hosts talk with 4 of our Diocesan Sems regarding their summer assignments and their studies.

We have a great interview today with Rachel Ogunsanwo. Today we will be talking from her life and book titled "Early Years of Marriage." She is a Veterinary Doctor by profession and a Counselor, Writer, Author, Speaker with passion. She is the founder of a closed Facebook group of over 6000 members for the past three years - Singles, Engaged and Married sisters(SEMs): the motto is premarital and marital counseling is our concern. She is also the founder of HAVILLAH HAVENS: a ministry of comfort, where people are encouraged, supported and counseled using outreaches, spiritual songs, and hymns, premarital/marital counseling, prayers of healing and faith, etc. She has written 6books, five of which are on marriage, relationships, parenting, and motherhood. She shares on unrealistic expectations and how many give up on the marriage too early if their expectations are not met. You can preview and purchase her ebooks at http://gumroad.com/rachelogunsanwo The video of this interview will be posted on Youtube soon. https://www.youtube.com/channel/UCR-jOnYMjtvoyVVUq2BO1ow?view= --- Support this podcast: https://anchor.fm/livingholisticallywell/support

YouTube is Beta-Testing New Viewer Applause Feature For now creators have to be invited by YouTube to test the new content monetization product, but it lets users support a video by paying $2 to put a clapping animation to appear over videos they like.  Editing and Uploading Instagram Stories May Get Even Easier This new option would provide a video slider trimming tool built into Stories. If it works, then users wouldn’t need third-party editing apps to trim their content before uploading. New Google Ads Partner Requirements Leave SEMs Frustrated SEMs are complaining about new requirements such as doubling the ad spend, upping certifications, and bowing to Google’s recommendations over what SEMs think is best for their clients.

Sems on break, recorded at the stroke of midnight. Home and parish life. Matt and Thomas are straight fire. Gratitude expressed.

There's no shortage of drama in the fastener industry, as surging optimism and idealistic youth align against ongoing consolidation and off-shoring. Throw in a few industry events and some fake news headlines and you get pretty exciting fastener talk radio. Jim “Big Papa” Kelam, of Sems and Specials weighs in on industry trends, Vegas, retirement, and the new breed of fastener pro, along with Jackie “Kind of a Big Deal” Ventura (1:09:20). YFP board member, Kenny Sanker, describes the AIM mentoring program (18:02). Also, SEFA president, Terry Windham previews the upcoming joint conference with SFA (34:09). Fastener News Report anchor, Mike McNulty and Baird analyst, Dave Manthey examine the shocking FDI numbers (40:10). Plus, senior fastener industry consultant, Carmen Vertullo gets fully threaded during the Fastener Training Minute (1:03:55). Brian and Eric remain philosophical as they play their role in the perennial saga that is the thread game. Run time: 01:50:07

Find the best summer reading by checking out these great sites!

Neuroaesthetics | Symposium Symposium im ZKM | Zentrum für Kunst und Medientechnologie, 22.-24. November 2012 In Kooperation und mit Unterstützung der Gemeinnützigen Hertie-Stiftung. Although music is generally acknowledged as a powerful tool for eliciting emotions, little is known concerning the neurobiological basis of these emotions. We investigated the psychological and neurobiological basis of strong emotional responses to music (SEM), leading to shivers down the spine (chills) and changes in heart rate. From previous studies it is known that these SEMs are accompanied by the activation of a brain network that includes areas involved in reward, emotion, and motivation. In order to observe distinct acoustical and music structural elements related to chill reactions, in a series of experiments, on-line emotional self report and psychophysiological data was obtained while participants were listening to music inducing strong emotions and aesthetic feelings. Despite of highly individual emotional reactions towards music, some interindividually constant characteristics of music eliciting chill responses can be found. Chills were much more frequent in previously known music and in familiar music stiles. Furthermore, distinct musical events frequently caused strong emotional responses, especially when violating expectancies. These results demonstrate that strong emotional responses are not only related to the psychoacoustic properties of the respective pieces of music, but furthermore to biographical memories, personality traits and social environments. Prof. Dr. med. Eckart Altenmüller is a full university professor and medical doctor, and has an active clinical and academic research career. He holds a Masters degree in Classical flute, and a M.D. and Ph.D. degree in Neurology and Neurophysiology. Between 1983 and 1985, he held a postdoctoral position in the department of Clinical Neurophysiology in Freiburg. In this position, he performed research into brain activation during auditory processing of music and learning of fine motor skills, an area in which he has published extensively. He received his clinical training in Neurology at the Department of Neurology at the University of Tübingen between 1985 and 1992, and was appointed Assistant Professor in Neurology in 1992. Since 1994 he is Chair and Director of the Institute of Music Physiology and Musicians’ Medicine at the University of Music Drama and Media in Hannover. He continues research into movement disorders in musicians as well as motor, auditory and sensory learning. He has published more than 120 peer reviewed papers on this topic and received 18 grants from the German Research Foundation (DFG). Since 2005 he is a member of the Göttingen Academy of Sciences.

SES Chicago 2007 Wrap, Yahoo Updates, MSN Webmasters, Promotion AdWords, YouTube Ads and In House SEM. We covered the SES show and our indepth coverage. We also discussed the Yahoo Search and Slurp updates. Microsoft is releasing a webmaster portal in late fall. We shared our opinions on Google’s new top promotion formula. Google began cashing in our YouTube, with ad overlays. And we chatted about the heated article on in-house SEMs.

We introduced the show with a look at how the industry including Google, Yahoo!, Microsoft, Ask.com and SEMs commemorated Halloween. I gave some insight from my stay at Yahoo! two weeks ago where I was shown first hand the new Panama ad system. We discussed the Did-It SEO versus PPC controversy.

Jafet är bilden för församlingen. Han bor i Sems tält och har till uppgift att utbreda sig. Det handlar om församlingens missionskallelse. Ham väljer bort fadern och är bilden för de som går förlorade för evigheten.